[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[2]
|
Yang, X.R., Chang-Claude, J., Goode, E.L., Couch, F.J., Nevanlinna, H., Milne, R.L., et al. (2011) Associations of Breast Cancer Risk Factors with Tumor Subtypes: A Pooled Analysis from the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 103, 250-263. https://doi.org/10.1093/jnci/djq526
|
[3]
|
Munzone, E., Curigliano, G., Rocca, A., Bonizzi, G., Renne, G., Goldhirsch, A., et al. (2005) Reverting Estrogen-Receptor-Negative Phenotype in HER-2-Overexpressing Advanced Breast Cancer Patients Exposed to Trastuzumab Plus Chemotherapy. Breast Cancer Research, 8, Article No. R4. https://doi.org/10.1186/bcr1366
|
[4]
|
Goldhirsch, A., Wood, W.C., Gelber, R.D., Coates, A.S., Thürlimann, B. and Senn, H.-J. (2003) Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. Journal of Clinical Oncology, 21, 3357-3365. https://doi.org/10.1200/JCO.2003.04.576
|
[5]
|
Allison, K.H., Hammond, M.E.H., Dowsett, M., McKernin, S.E., Carey, L.A., Fitzgibbons, P.L., et al. (2020) Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology, 38, 1346-1366. https://doi.org/10.1200/JCO.19.02309
|
[6]
|
Chen, T., Zhang, N., Moran, M.S., Su, P., Haffty, B.G. and Yang, Q. (2018) Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit from Endocrine Therapy: A Systematic Review and Meta-Analysis. Clinical Breast Cancer, 18, 1-8. https://doi.org/10.1016/j.clbc.2017.06.005
|
[7]
|
Collins, L.C., Botero, M.L. and Schnitt, S.J. (2005) Bimodal Frequency Distribution of Estrogen Receptor Immunohistochemical Staining Results in Breast Cancer. American Journal of Clinical Pathology, 123, 16-20.
https://doi.org/10.1309/HCF035N9WK40ETJ0
|
[8]
|
Peterson, T.J., Karmakar, S., Pace, M.C., Gao, T. and Smith, C.L. (2007) The Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) Corepressor Is Required for Full Estrogen Receptor α Transcriptional Activity. Molecular and Cellular Biology, 27, 5933-5948. https://doi.org/10.1128/MCB.00237-07
|
[9]
|
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., et al. (2007) Estrogen Receptors: How Do They Signal and What Are Their Targets. Physiological Reviews, 87, 905-931.
https://doi.org/10.1152/physrev.00026.2006
|
[10]
|
Ketchart, W., Ogba, N., Kresak, A., Albert, J.M., Pink, J.J. and Montano, M.M. (2011) HEXIM1 Is a Critical Determinant of the Response to Tamoxifen. Oncogene, 30, 3563-3569. https://doi.org/10.1038/onc.2011.76
|
[11]
|
Sahab, Z.J., Man, Y.-G., Semaan, S.M., Newcomer, R.G., Byers, S.W. and Sang, Q.-X.A. (2010) Alteration in Protein Expression in Estrogen Receptor Alpha-Negative Human Breast Cancer Tissues Indicates a Malignant and Metastatic Phenotype. Clinical & Experimental Metastasis, 27, 493-503. https://doi.org/10.1007/s10585-010-9338-8
|
[12]
|
Rizza, P., Barone, I., Zito, D., Giordano, F., Lanzino, M., De Amicis, F., et al. (2014) Estrogen Receptor Beta as a Novel Target of Androgen Receptor Action in Breast Cancer Cell Lines. Breast Cancer Research, 16, Article ID: R21.
https://doi.org/10.1186/bcr3619
|
[13]
|
Hammond, M.E.H., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., et al. (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recom-mendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 28, 2784-2795.
https://doi.org/10.1200/JCO.2009.25.6529
|
[14]
|
Yi, M., Huo, L., Koenig, K.B., Mittendorf, E.A., Meric-Bernstam, F., Kuerer, H.M., et al. (2014) Which Threshold for ER Positivity? A Retrospective Study Based on 9639 Patients. Annals of Oncology, 25, 1004-1011.
https://doi.org/10.1093/annonc/mdu053
|
[15]
|
Harvey, J.M., Clark, G.M., Osborne, C.K. and Allred, D.C. (1999) Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 17. 1471-1481. https://doi.org/10.1200/JCO.1999.17.5.1474
|
[16]
|
Poon, I.K., Tsang, J.Y., Li, J., Chan, S., Shea, K. and Tse, G.M. (2020) The Significance of Highlighting the Oestrogen Receptor Low Category in Breast Cancer. British Journal of Cancer, 123, 1223-1227.
https://doi.org/10.1038/s41416-020-1009-1
|
[17]
|
Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., et al. (2011) Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-Analysis of Randomised Trials. Lancet, 378, 771-784. https://doi.org/10.1016/S0140-6736(11)60993-8
|
[18]
|
Fujii, T., Kogawa, T., Dong, W., Sahin, A.A., Moulder, S., Litton, J.K., et al. (2017) Revisiting the Definition of Estrogen Receptor Positivity in HER2-Negative Primary Breast Cancer. Annals of Oncology, 28, 2420-2428.
https://doi.org/10.1093/annonc/mdx397
|
[19]
|
DeCensi, A., Puntoni, M., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L., et al. (2019) Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. Journal of Clinical Oncology, 37, 1629-1637. https://doi.org/10.1200/JCO.18.01779
|
[20]
|
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-Month analysis of the ATAC Trial. The Lancet Oncology, 9, 45-53. https://doi.org/10.1016/S1470-2045(07)70385-6
|
[21]
|
Keen, J.C. and Davidson, N.E. (2003) The Biology of Breast Carcinoma. Cancer, 97, 825-833.
https://doi.org/10.1002/cncr.11126
|
[22]
|
Ellis, M.J., Llombart-Cussac, A., Feltl, D., Dewar, J.A., Jasiówka, M., Hewson, N., et al. (2015) Fulvestrant 500 mg versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis from the Phase II FIRST Study. Journal of Clinical Oncology, 33, 3781-3787. https://doi.org/10.1200/JCO.2015.61.5831
|
[23]
|
Yu, K., Cai, Y., Wu, S., Shui, R. and Shao Z. (2021) Estrogen Receptor-Low Breast Cancer: Biology Chaos and Treatment Paradox. Cancer Communications, 41, 968-980. https://doi.org/10.1002/cac2.12191
|
[24]
|
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., et al. (2017) Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine, 376, 2147-2159.
https://doi.org/10.1056/NEJMoa1612645
|
[25]
|
Colleoni, M., Gray, K.P., Gelber, S., Láng, I., Thürlimann, B., Gianni, L., et al. (2016) Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Recep-tor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. Journal of Clinical Oncolog, 34, 3400-3408.
https://doi.org/10.1200/JCO.2015.65.6595
|
[26]
|
Iwase, H., Greenman, J., Barnes, D., Bobrow, L., Hodgson, S. and Mathew, C. (1995) Loss of Heterozygosity of the Oestrogen Receptor Gene in Breast Cancer. British Journal of Cancer, 71, 448-450.
https://doi.org/10.1038/bjc.1995.91
|
[27]
|
Tsuboi, K., Nagatomo, T., Gohno, T., Higuchi, T., Sasaki, S., Fujiki, N., et al. (2017) Single CpG Site Methylation Controls Estrogen Receptor Gene Transcription and Correlates with Hormone Therapy Resistance. The Journal of Steroid Biochemistry and Molecular Biology, 171, 209-217. https://doi.org/10.1016/j.jsbmb.2017.04.001
|
[28]
|
Mansoori, B., Mohammadi, A., Gjerstorff, M.F., Shirjang, S., Asadzadeh, Z., Khaze, V., et al. (2019) miR-142-3p Is a Tumor Suppressor That Inhibits Estrogen Receptor Expression in ER-Positive Breast Cancer. Journal of Cellular Physiology, 234, 16043-16053. https://doi.org/10.1002/jcp.28263
|
[29]
|
Li, L., Li, Z., Howley, P.M. and Sacks, D.B. (2006) E6AP and Calmodulin Reciprocally Regulate Estrogen Receptor Stability. Journal of Biological Chemistry, 281, 1978-1985. https://doi.org/10.1074/jbc.M508545200
|
[30]
|
Oh, A.S., Lorant, L.A., Holloway, J.N., Miller, D.L., Kern, F.G. and El-Ashry, D. (2001) Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells. Molecular Endocrinology, 15, 1344-1359.
https://doi.org/10.1210/mend.15.8.0678
|